252 related articles for article (PubMed ID: 17096015)
1. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
2. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
4. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Jagannath S; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Cowan JM; Anderson KC
Leukemia; 2007 Jan; 21(1):151-7. PubMed ID: 17096017
[TBL] [Abstract][Full Text] [Related]
7. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
8. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
9. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG; Mitsiades C; Ghobrial I; Anderson K
Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
[TBL] [Abstract][Full Text] [Related]
10. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G; Hansen T; Shimoni A; Zabelina T; Pérez-Simón JA; Gutierrez NC; Bethge W; Liebisch P; Schwerdtfeger R; Bornhäuser M; Otterstetter S; Penas EM; Dierlamm J; Ayuk F; Atanackovic D; Bacher U; Bokemeyer C; Zander A; San Miguel J; Nagler A; Kröger N
Leukemia; 2008 Jun; 22(6):1250-5. PubMed ID: 18418408
[TBL] [Abstract][Full Text] [Related]
11. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
12. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M; Kobayashi T; Fuchida S; Yamamoto-Sugitani M; Ohshiro M; Shimura Y; Mizutani S; Nagoshi H; Sasaki N; Nakayama R; Chinen Y; Sakamoto N; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Kuroda J; Taniwaki M
Int J Hematol; 2012 May; 95(5):516-26. PubMed ID: 22426624
[TBL] [Abstract][Full Text] [Related]
13. [IgA multiple myeloma with adverse prognostic factors--a case report].
Kumiega B; Wolska-Smoleń T; Skotnicki AB
Przegl Lek; 2009; 66(8):459-63. PubMed ID: 20043594
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
16. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
18. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Avet-Loiseau H; Soulier J; Fermand JP; Yakoub-Agha I; Attal M; Hulin C; Garderet L; Belhadj K; Dorvaux V; Minvielle S; Moreau P;
Leukemia; 2010 Mar; 24(3):623-8. PubMed ID: 20072152
[TBL] [Abstract][Full Text] [Related]
19. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
